Product Description

DFNA5 Rabbit Monoclonal Antibody

Catalogue Numbers: MB66335-50, MB66335-100

Sizes: 50µl, 100µl

Product: Liquid in 50mM Tris-Glycine (pH 7.4), 0.15M NaCl, 50% Glycerol, 0.01% Sodium azide and 0.05% BSA.

Swiss-Prot: O60443

Host: Rabbit

Reactivity: Human

Applications: WB, IP

All Applications: WB (1/500 - 1/1000), IP (1/10 - 1/50)

Background: The gasdermin family that includes GSDMA, GSDMB, GSMDC, GSDMD, and GSDME have been shown to play a role in inflammation and cell death. Gasdermin D has been reported to have a critical role as a downstream effector of pyroptosis. Pyroptosis is a lytic type of cell death triggered by inflammasomes, multiprotein complexes assembled in response to pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) that result in the activation of caspase-1 and subsequent cleavage of pro-inflammatory cytokines IL-1β and IL-18. Gasdermin D was identified by two independent groups as a substrate of inflammatory caspases, caspase-1 and caspase-11/4/5, producing two fragments: GSDMD-N and GSDMD-C. Cleavage results in release of an intramolecular inhibitory interaction between the N- and C-terminal domains, allowing the N-terminal fragment GSDMD-N to initiate pyroptosis through the formation of pores on the plasma membrane. Gasdermin E (GSDME), also known as DFNA5, was originally identified as a genetic cause of nonsyndromic hearing loss. Like other gasdermin family members, Gasdermin E contains an amino-terminal pore forming domain that triggers pyroptosis. Cleavage of Gasdermin E at Asp270 is induced by apoptotic-associated caspase-3, converting apoptotic signals to pyroptosis. In addition, cleavage of Gasdermin E can be induced by Granzyme B secreted by NK cells and contributes to tumor suppressive activity. Gasdermin E expression is suppressed in several types of cancer including gastric, colorectal, and breast carcinoma, and may be associated with decreased survival. In contrast, an increase in Gasdermin E, including the amino-terminal pore-forming fragment, is associated with conditions of excessive inflammation.

Purification and Purity: The antibody was purified by immunogen affinity chromatography.

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: Recognizes endogenous levels of DFNA5 protein.

Extra Notes: Western blot analysis of DFNA5 expression in U251MG (A), U2OS (B), HepG2 (C), Hela (D) whole cell lysates.

Bioworld Molecular Weight: ~ 55 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Name: Gasdermin-E; Inversely correlated with estrogen receptor expression 1; ICERE-1; Non-syndromic hearing impairment protein 5; DFNA5; ICERE1

Immunogen: Recombinant protein of human DFNA5/GSDME

Conjugate: Unconjugated

Modification: Unmodified